Corcept Therapeutics Incorporated (CORT) News
Filter CORT News Items
CORT News Results
| Date | Symbol | Company | Title | Start | End | Change | POWR Rating | ||
|---|---|---|---|---|---|---|---|---|---|
| Loading, please wait... | |||||||||
CORT News Highlights
- For CORT, its 30 day story count is now at 3.
- Over the past 13 days, the trend for CORT's stories per day has been choppy and unclear. It has oscillated between 1 and 1.
- DRRX, DRUG and ROAD are the most mentioned tickers in articles about CORT.
Latest CORT News From Around the Web
Below are the latest news stories about CORCEPT THERAPEUTICS INC that investors may wish to consider to help them evaluate CORT as an investment opportunity.
Estimating The Intrinsic Value Of Corcept Therapeutics Incorporated (NASDAQ:CORT)In this article we are going to estimate the intrinsic value of Corcept Therapeutics Incorporated ( NASDAQ:CORT ) by... |
Corcept (CORT) Rides on Robust Korlym Sales, High Reliance a WoeCorcept's (CORT) Cushing's syndrome drug Korlym is witnessing higher sales and a strong uptake since approval. However, sole dependence on Korlym for revenues remains a headwind. |
Durect (DRRX) Soars 11.8%: Is Further Upside Left in the Stock?Durect (DRRX) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further strength down the road. |
7 Undervalued Biotech Stocks to Buy Before They BoomWhile medical innovations offer tremendous appeal, investors can still get a discount in this sector via undervalued biotech stocks to buy. |
Corcept Therapeutics Incorporated's (NASDAQ:CORT) Stock Has Shown Weakness Lately But Financial Prospects Look Decent: Is The Market Wrong?It is hard to get excited after looking at Corcept Therapeutics' (NASDAQ:CORT) recent performance, when its stock has... |
Why Corcept Therapeutics (CORT) is a Top Growth Stock for the Long-TermThe Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage. |
Our 7 Top Biotech Stock Picks for 2023Following the devastation of Covid-19, there’s greater interest toward medical innovations, thus bolstering biotech stock picks for 2023. |
Corcept Therapeutics Settles Patent Litigation with Hikma PharmaceuticalsMENLO PARK, Calif., Dec. 08, 2022 (GLOBE NEWSWIRE) -- Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of medications to treat severe endocrine, oncologic, metabolic and neurological disorders by modulating the effects of the hormone cortisol, today announced that it has entered into an agreement with Hikma Pharmaceuticals USA Inc. ("Hikma") resolving patent litigation related to Korlym®, Corcept’s medication for the treatment |
Corcept Therapeutics Provides Miricorilant Clinical Development UpdateMENLO PARK, Calif., Dec. 08, 2022 (GLOBE NEWSWIRE) -- Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of medications to treat severe endocrine, oncologic, metabolic and neurological disorders by modulating the effects of the hormone cortisol, today announced an update to its programs evaluating the proprietary selective cortisol modulator miricorilant in patients with antipsychotic-induced weight gain (AIWG) and non-alcoholic |
Jefferies Sticks to Its Buy Rating for Corcept Therapeutics (CORT)Jefferies analyst Dennis Ding maintained a Buy rating on Corcept Therapeutics (CORT - Research Report) yesterday and set a price target of $35.00. The company's shares closed yesterday at $26.07.According to TipRanks, Ding is an analyst with an average return of -27.1% and a 29.41% success rate. Ding covers the Healthcare sector, focusing on stocks such as Corcept Therapeutics, NGM Biopharmaceuticals, and Roivant Sciences.Currently, the analyst consensus on Corcept Therapeutics is a Moderate Buy with an average price target of $32.00, implying a 22.75% upside from current levels. In a report released on November 7, H.C. Wainwright also maintained a Buy rating on the stock with a $33.00 price target. |